Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data
Sponsor: Pfizer
Listed as NCT04647110, this observational or N/A phase trial focuses on ALK-positive NSCLC and remains completed. Sponsored by Pfizer, it has been updated 10 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2023 — Jul 2024 [monthly]
Completed
-
Jan 2023 — May 2023 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 5 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Completed
-
Jun 2021 — Sep 2022 [monthly]
Completed
Status: Recruiting → Completed
-
Mar 2021 — Jun 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .